drugset / Trial / NCT03026205
ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)
Phase 2
Withdrawn
University of Toledo Health Science Campus
ARMS Pharmaceutical LLC · collabPediatric Pharmacology Research Center · collabProMedica Health System · collabThe University of Toledo · collab
NaSingle-groupOpen-labelOther
Summary
This is a single center study to evaluate the pharmacokinetics of ARMS-I a formulation that incorporates cetylpyridinium chloride (CPC), administered once as a single dose of three sprays orally, followed by multiple dosing (3x daily oral sprays) over days 3-6 and then a repeat pharmacokinetic study during the final oral dose administered as the first dose on day 7 to ascertain CPC accumulation.
Timeline
- Start
- 2017-01
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetylpyridinium | Small molecule | 0.75 mg | Oral |